Injective
Why Injective is down 1.6% in the last hour
Analysis
Injective (INJ) slipped 1.6% over the past hour despite a bullish headline, suggesting traders may have sold into the news rather than extend the rally. The move comes as The Block reported Injective CEO Eric Chen expects US INJ ETFs to launch sooner than 2027, but the market reaction in the short term appears muted and slightly risk-off.
Contributing Factors (1)
Injective CEO Eric Chen expects US INJ ETFs to launch sooner than 2027
There are currently two ETF applications tied to INJ — the 21Shares Injective ETF and the Canary Staked INJ ETF.
Move Details
Explanation Confidence
High confidence in the explanation based on source reliability and timing.